• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 1
  • Tagged with
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Valida??o de um teste r?pido imunocromatogr?fico para semi-quantifica??o de ant?geno prost?tico espec?fico em soro humano

Espindola Filho, Jorge Luis 15 May 2015 (has links)
Submitted by Setor de Tratamento da Informa??o - BC/PUCRS (tede2@pucrs.br) on 2015-09-14T11:12:12Z No. of bitstreams: 1 474772 - Texto Completo.pdf: 1124242 bytes, checksum: fab9ded47ccf23deb14095b1140f7d8d (MD5) / Made available in DSpace on 2015-09-14T11:12:13Z (GMT). No. of bitstreams: 1 474772 - Texto Completo.pdf: 1124242 bytes, checksum: fab9ded47ccf23deb14095b1140f7d8d (MD5) Previous issue date: 2015-05-15 / Around 1.1 million cases of prostate cancer are estimated worldwide every year, accounting for more than 250,000 deaths. It is widely known that the improvement on patients' prognosis is due to an early diagnosis of this neoplasm. Although the Prostate Specific Antigen (PSA) has some limitations concerning sensitivity and specificity for the pathology in question, its serum dosage is used in many countries as a tool for screening and early detection of prostate cancer, which makes it one of the most used devices since its discovery. In 2014, the Brazilian public health system authorized more than 4.8million tests of this kind. Considering the territorial and economic heterogeneity of the Brazilian population, it is necessary to the develop tests with low cost and easy application, which will assist the diagnosis of prostate cancer, without sacrificing sensitivity and specificity. Thus, this study means to validate a rapid test for semi-quantification of PSA in human serum, developed by the Brazilian company FK Biotechnology. At the end of the study, the product showed diagnostic sensitivity of 100% and specificity of 85.71%, being considered satisfactory for a preliminary test, but requiring subsequent adjustments. / Cerca de 1 milh?o e 100 mil casos de c?ncer de pr?stata s?o estimados no mundo anualmente, respons?veis por mais de 250 mil ?bitos. Sabe-se que a melhora do progn?stico dos pacientes deve-se a um diagn?stico precoce desta neoplasia. Embora o Ant?geno Prost?tico Espec?fico (PSA) tenha limita??es do ponto de vista de sensibilidade e especificidade para a patologia em destaque, sua dosagem s?rica ? utilizada em muitos pa?ses como ferramenta para o rastreamento e detec??o precoce de c?ncer de pr?stata, caracterizando-o como uma das ferramentas mais utilizadas desde sua descoberta. Em 2014, o sistema p?blico de sa?de brasileiro autorizou aproximadamente mais de 4,8 milh?es de testes como este. Levando em considera??o a heterogeneidade territorial e econ?mica da popula??o do Brasil, ? necess?ria a elabora??o de ensaios de baixo custo e f?cil aplica??o que possam auxiliar no diagn?stico do c?ncer de pr?stata, sem abrir m?o da sensibilidade e especificidade. Desta forma, o presente trabalho consistiu na valida??o de um teste r?pido desenvolvido por uma empresa brasileira de biotecnologia para semi-quantifica??o de PSA em soro humano. Ao final do estudo, o produto apresentou sensibilidade diagn?stica = 100% e especificidade = 85,71%, sendo considerado satisfat?rio para um teste preliminar, mas necessitando ajustes posteriores.

Page generated in 0.0269 seconds